Core Viewpoint - The company reported a significant increase in R&D costs and a reduction in losses for the first half of 2025, indicating ongoing investment in clinical development and product licensing [1] Financial Performance - R&D costs amounted to approximately 132 million, representing a year-on-year increase of 56.9% [1] - The company incurred a loss of approximately 166 million, which is a 7.8% decrease compared to the previous year [1] - The loss per share was reported at 1.06 [1] Key Drivers of R&D Cost Increase - The increase in R&D costs was primarily due to: - Increased milestone expenditures related to the preparation for the submission of the Biologics License Application (BLA) for LBL-024 [1] - Higher clinical development expenses, mainly due to accelerated patient enrollment and clinical progress for LBL-024 and LBL-034 [1]
维立志博-B(09887)公布中期业绩 净亏损约1.66亿元 同比减少7.8%